ER-POSITIVE BREAST CANCER
Clinical trials for ER-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug trial halted: VLS-101 shows limited promise
Disease control TerminatedThis study tested a drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to other treatments. The goal was to see if the drug could shrink tumors. The trial was ended early, and …
Matched conditions: ER-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 01, 2026 16:00 UTC
-
New combo therapy for rare breast cancer type shows early safety focus
Disease control TerminatedThis early-phase study tested a new drug (infigratinib) combined with tamoxifen in people with a specific advanced breast cancer (hormone receptor-positive, HER2-negative, with FGFR gene changes). The main goal was to find a safe dose and check for side effects. Only 4 people too…
Matched conditions: ER-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC